What is Zacks Research’s Forecast for BDX FY2025 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research lowered their FY2025 earnings per share estimates for Becton, Dickinson and Company in a research note issued to investors on Monday, December 16th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $14.39 per share for the year, down from their previous estimate of $14.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.25 EPS, Q2 2026 earnings at $3.83 EPS, Q3 2026 earnings at $4.01 EPS, Q4 2026 earnings at $4.49 EPS and FY2026 earnings at $15.51 EPS.

A number of other equities research analysts have also recently weighed in on BDX. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $223.83 on Thursday. The business’s fifty day moving average is $230.06 and its 200 day moving average is $233.27. The stock has a market cap of $64.71 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 1.64 and a beta of 0.41. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company earned $3.42 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s payout ratio is presently 70.03%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now directly owns 14,217 shares in the company, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently bought and sold shares of BDX. Lord Abbett & CO. LLC lifted its position in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Lord Abbett & CO. LLC now owns 195,858 shares of the medical instruments supplier’s stock valued at $47,221,000 after buying an additional 1,022 shares in the last quarter. Copley Financial Group Inc. purchased a new position in Becton, Dickinson and Company during the third quarter valued at approximately $457,000. Oddo BHF Asset Management Sas purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth $522,000. Peapack Gladstone Financial Corp raised its position in shares of Becton, Dickinson and Company by 2.1% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 101,600 shares of the medical instruments supplier’s stock valued at $24,497,000 after purchasing an additional 2,057 shares during the period. Finally, Synovus Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 9.8% during the 3rd quarter. Synovus Financial Corp now owns 9,017 shares of the medical instruments supplier’s stock valued at $2,174,000 after buying an additional 808 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.